B A C K G R O U N D Description of the condition
Rates of gestational diabetes mellitus (GDM), defined as hyperglycaemia with blood glucose values above normal, but below those diagnostic of diabetes which occurs during pregnancy and usually returning to normal after birth (WHO 2013) , are rising worldwide (Ferrara 2007) . Women with GDM have a greater degree of insulin resistance compared with women without GDM, which leads to maternal hyperglycaemia and transport of glucose across the placenta to the developing fetus (Setji 2005) . GDM is thought to result from an inadequate compensatory response to this insulin-resistant state caused by hormonal changes in pregnancy (Buchanan 1990; Setji 2005) . The multifaceted aetiology of GDM is demonstrated in its many risk factors, which include advanced maternal age, maternal obesity, certain ethnicities, family history of diabetes, and previous history of GDM, macrosomia or neonatal death (Berkowitz 1992; Chu 2007; Khan 2013; Solomon 1997; Theriault 2014; Xiong 2001) . Whilst a number of risk factors have been identified, exactly how each contributes to the development of GDM is uncertain. Nevertheless, some of these risk factors are modifiable and can be targeted in preventive interventions. Health risks for women with GDM include pre-eclampsia and induction of labour (Crowther 2005) , and more than half will develop type 2 diabetes within 10 years after giving birth (Kim 2002) . There are well-documented risks for infants born to mothers with GDM, including being large-for-gestational age, macrosomia, respiratory distress syndrome, jaundice, hypoglycaemia, and birth injuries such as nerve palsy, bone fracture and shoulder dysto-cia (Adams 1998; Crowther 2005; Gonzalez-Quintero 2007; He 2015; Landon 2009; Langer 2005) . In addition there is increasing recognition of intrauterine programming effects and adverse longterm health consequences into childhood and adulthood that include obesity, diabetes, and the metabolic syndrome (Boney 2005; Cho 2000) .
Description of the interventions
Given the multifaceted aetiology of GDM, interventions aimed at preventing GDM may target a variety of risk factors. Multiple approaches, including diet, physical activity, dietary supplements and pharmaceutical interventions, have been proposed for GDM prevention. Interventions are often multifaceted, combining one or more approaches. Food-based interventions have focused primarily on minimising the impact of diet on glycaemic response through low glycaemic index or high fibre diets (Fraser 1983; Fraser 1988; Markovic 2015) . The role of a number of dietary supplements in preventing GDM, such as probiotics, myo-inositol, vitamin D and fish oils, have also been investigated ( There are a number of oral anti-diabetic pharmaceutical therapies, including sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides and peptide analogues, although the safety of many of these for use in pregnancy is unclear (Holt 2014; Slocum 2002) . Metformin or glibenclamide are the only oral hypoglycaemics recommended for use in pregnancy (ACOG 2013; NICE 2015) , although these are not currently licensed for use in pregnancy (Skupien 2014) . Interventions identified as having a potential role in the prevention of GDM have also targeted women at preconception or interconception time points, particularly in women at high risk of GDM such as those who are overweight or obese (Yeung 2010) or have a history of GDM (Khan 2013).
How the intervention might work

Dietary interventions
A number of components of the diet may influence GDM risk through direct and indirect effects on glycaemic response, and these may have an additive effect (Ley 2011; Rogozinska 2015; Zhang 2006) . High intake of simple sugars has been associated with reduced insulin sensitivity and insulin secretion (Davis 2005; Reiser 1979) , while intake of whole grain foods, cereal fibre and low glycaemic index foods have been associated with lower insulin resistance. Chronic increased insulin demand through a high intake of simple sugars may lead to pancreatic exhaustion, resulting in glucose intolerance (Ludwig 2002) . On the other hand, fibre intake slows digestion ( Calorie restriction may reduce the risk of GDM through consequent weight loss and reduced fat mass, leading to improvements in insulin sensitivity and glycaemic status (Knopp 1991; Larson-Meyer 2006) . However, excessive calorie restriction can lead to ketonaemia and ketonuria through 'starvation ketosis' (Magee 1990; Metzger 2007) . Reports of detrimental effects of maternal ketones on foetal development has raised concerns about the safety of severe calorie restriction and weight loss during pregnancy (Churchill 1969; Ornoy 1998; Rizzo 1991 
Physical activity interventions
Regular physical activity, both before and during pregnancy, has been associated with a reduced risk of GDM (Dempsey 2004; Zhang 2014) . Physical activity affects energy expenditure and therefore directly affects glucose utilisation. Physical activity enhances glucose uptake through translocation of the glucose transporter type 4 (GLUT-4) on skeletal muscle (Kennedy 1999). Insulin sensitivity is increased with physical activity, with effects continuing after exercise is ceased (Perseghin 1996) . Increased muscle mass as a result of physical activity is likely to further improve glucose tolerance and increase insulin sensitivity (Yki-Jarvinen 1983).
Diet and physical activity combined
Given that a number of lifestyle factors such as diet, physical activity and body mass index contribute to the risk of developing GDM, targeting several factors simultaneously may be synergistic. Lifestyle interventions targeting diet, physical activity and weight loss have had promising results for the prevention of type 2 dia-betes in high-risk individuals (Knowler 2002; Tuomilehto 2001) , and may have similar effects in preventing GDM.
Dietary supplements Probiotics
Probiotics are live micro-organisms that, when administered in adequate amounts, may confer a health benefit to the host ( 
Myo-inositol
Myo-inositol is a polyol (Croze 2013) that occurs naturally in the diet, is present in certain fruit, vegetables, beans, nuts, seeds and grains, (Clements 1980) and is thought to mimic the action of insulin (Croze 2013; Saltiel 1990 ). Myo-inositol acts as a mediator in the insulin-signalling cascade (Baillargeon 2010), and has been shown to improve insulin sensitivity (Corrado 2011) through the enhancement of GLUT-4 translocation in skeletal muscle (Dang 2010) . 
Fish oil
Differences in circulating concentrations of long-chain polyunsaturated fatty acids are seen in women with GDM compared with women without GDM (Wijendran 1999). It has been hypothesised that omega-3 long-chain polyunsaturated fatty acids consumed in the diet, primarily in the form of oily fish or fish oil supplements (Kris-Etherton 2000; Kris-Etherton 2009), are incorporated into peripheral and pancreatic cell membranes. This is thought to enhance insulin secretion, insulin receptor binding and insulin sensitivity, thereby enhancing glucose transport across peripheral cell membranes and improving glucose homeostasis (Lardinois 1987). Omega-3 fatty acids may further modulate diabetes risk through their anti-inflammatory properties (Calder 2006) .
Pharmaceutical interventions
Metformin improves insulin sensitivity and hyperglycaemia ( Jackson 1987) by reducing gluconeogenesis in the liver (Stumvoll 1995; Wollen 1988) and enhancing peripheral glucose uptake and utilisation by altering metabolic pathways (Viollet 2012). Metformin may therefore protect against GDM by reducing insulin resistance and preserving pancreatic β-cell reserves during pregnancy, when both insulin resistance and insulin secretion are increased (Kazi 2015).
Preconception or interconception interventions
Preconception and interconception are key time points for the identification of risk factors for complications during pregnancy, including GDM, and are opportune times to provide advice on strategies to improve health and pregnancy outcomes (Hanson 2015; Jack 1990) . Targeting modifiable risk factors such as weight gain, overweight or obesity may reduce the risk of GDM in subsequent pregnancies (Pole 1999).
Why it is important to do this overview
GDM affects an increasing number of pregnant women each year, posing significant health risks to both mother and infant. A number of risk factors for GDM, such as physical inactivity and being overweight or obese prior to pregnancy, are potentially modifiable and while different strategies have shown promise in the prevention of GDM, it is currently unclear which strategies are effective. Primary prevention of GDM rather than treatment would lead to economic (Danyliv 2014) and health benefits. This overview will provide an important resource for all healthcare professionals caring for pregnant women, guideline developers, policy makers, researchers, women who are at risk of developing GDM and their families. Use of the overview to identify and then target effective preventive interventions may contribute to reducing the incidence of GDM and the associated short-and long-term health risks for the mother and her child. Further, this overview may identify areas requiring further research.
O B J E C T I V E S
To summarise the evidence from Cochrane systematic Reviews regarding the effects of interventions for preventing gestational diabetes mellitus.
In this overview of systematic reviews, we will include only published Cochrane systematic Reviews, assessing interventions for prevention of gestational diabetes mellitus (GDM), reporting GDM as a primary or secondary review outcome. We will identify Cochrane protocols and titles for future inclusion, and classify them as 'ongoing reviews' (in an appendix). If a review identified for inclusion is more than two years out of date, we will contact the review authors to ascertain when the review will be updated. If such a review is out of date and is not going to be updated in time to be included in the overview, we will include the last published version and acknowledge this as a limitation.
Participants
We will include reviews that cover women planning a pregnancy or pregnant women. We will exclude reviews covering women with pre-existing type 1 or type 2 diabetes.
Interventions
We will include lifestyle, dietary supplement, pharmacological and other interventions used to prevent GDM and implemented prior to GDM screening, including:
1. dietary interventions; 2. physical activity interventions; 3. combined dietary and physical activity interventions; 4. dietary supplement interventions (e.g. probiotics, myoinositol, vitamin D and omega-3 fatty acids); 5. pharmaceutical interventions (e.g. oral anti-diabetic pharmaceutical therapies); 6. other interventions for prevention not detailed above. We will include Cochrane systematic Reviews evaluating interventions administered at preconception, interconception and during pregnancy. We will include reviews evaluating interventions compared with a control, as well as those evaluating one intervention compared with another intervention.
Outcomes Primary outcomes
Maternal outcomes
• Diagnosis of GDM (as defined by systematic review authors)
• Hypertensive disorders of pregnancy (including preeclampsia, pregnancy-induced hypertension and eclampsia) 
Search methods for identification of reviews
We will search the Cochrane Database of Systematic Reviews for any systematic reviews or protocols that examine interventions for the preventing GDM. Key words that we will use for the search are 'gestational diabetes' OR 'GDM' OR 'diabetes AND pregnancy'. We will use the search terms to search 'all text', and not limited to 'title, abstract, or keywords'. We will not apply any language or date restrictions.
Data collection and analysis
We will base the methodology for data collection and synthesis on Chapter 22, 'Overviews of Reviews' in the Cochrane Handbook of Systematic Reviews of Interventions (Becker 2011).
Selection of reviews
Two overview authors will independently assess for potential inclusion all Cochrane systematic Reviews we identify that evaluate the effects of interventions for GDM prevention. We will resolve any disagreement through discussion or, if required, through consultation with a third overview author.
Data extraction and management
Two of the overview authors will independently extract data, using an electronic form which we will design and pilot. We will resolve disagreements by consensus or by recourse to a third overview author. If any information from the reviews is missing, we will contact the systematic review authors for further details. We will extract and tabulate information for the following:
Review characteristics
• Review title and authors.
• Search date: date of search conducted by review (we will consider less than two years ago to be current).
• The number of trials in the review, number of women and their infants.
• The population demographics: we will produce a summary of the participant characteristics in the included reviews.
• Quality of the included trials (as reported by the review authors; see 'Quality of included studies within reviews' below, under Assessment of methodological quality of included reviews).
• Interventions and comparisons relevant to this overview.
• All prespecified outcomes relevant to this overview as listed below.
• Any other characteristics required to assess and report on review quality (see 'Quality of included reviews' under Assessment of methodological quality of included reviews).
Outcomes
Maternal outcomes:
• Diagnosis of GDM • Hypertensive disorders of pregnancy (including preeclampsia, pregnancy-induced hypertension and eclampsia)
• Gestational weight gain
Child (as a fetus, neonate, child, adult) outcomes:
• Large-for-gestational age • Summary intervention effects by intervention, including the pooled effects (e.g. risk ratios, odds ratios, mean differences, standardised mean differences, or numbers needed to treat), 95% confidence intervals, and numbers of studies and participants contributing data to each pooled effect for the overview's maternal and child outcomes.
• Information required to assess and report on the quality of the evidence for the intervention effects extracted above (see 'Quality of evidence in included reviews' under Assessment of methodological quality of included reviews).
• Where reviews were not able to perform meta-analyses and therefore did not report statistical summaries, we plan to extract from those reviews the narrative text relating to the results for our overview outcomes.
To describe the extent of the evidence available from the systematic reviews of interventions included in the overview, we will include a table (as an appendix) that uses the outcomes agreed on by consensus by the authors of Cochrane systematic Reviews for prevention and treatment of GDM (Appendix 1), and shows for each systematic review included in the overview whether or not there were data for these outcomes included in the systematic review, and will document any additional outcomes that the systematic review reported. We will not extract data for all these outcomes but only data for the GRADE outcomes prespecified for this overview.
We will assess the methodological quality of each systematic review using the ROBIS (Risk of Bias in Systematic reviews) tool (Whiting 2015) . The ROBIS tool consists of three phases; the first assesses the relevance of the systematic review to the research question, the second identifies concerns with the review process, and the third judges the risk of bias across four domains.
• Study eligibility criteria • Identification and selection of studies • Data collection and study appraisal • Synthesis and findings
Signalling questions are used to assess specific concerns about potential biases within the review, and the ratings from these questions are used to judge overall risk of bias. The signalling questions are answered as 'yes', 'probably yes', 'probably no', 'no' or 'no information'. The subsequent level of concern about bias associated with each domain is then judged as 'low', 'high', or 'unclear'. If the answers to all signalling questions for a domain are 'yes' or 'probably yes', the level of concern can be judged as low. If any signalling question is answered 'no' or 'probably no', the potential for concern about bias exists.
Quality of evidence in the included reviews
We will assess the quality of the evidence from each review using the GRADE system for the outcomes listed above. Where available, we will use the GRADE 'Summary of findings' tables from the included Cochrane systematic Reviews. Where such a table is not available, we will produce one using GRADE Profiler software ( GRADEpro). The GRADE system assesses the following features for the evidence found for selected outcomes.
• Risk of bias: internal validity of the evidence • Inconsistency: heterogeneity or variability in the estimates of effect across studies
• Indirectness: degree of differences between population, intervention and outcome of interest
• Imprecision (random error): extent to which confidence in the effect estimate is adequate to support a particular decision
• Risk of publication bias: degree of selective publication of studies The GRADE system rates the quality of the evidence as:
• high (further research is very unlikely to change confidence in the estimate of the effect);
• moderate (further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate);
• low (further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate);
• very low (any estimate of effect is very uncertain).
We will summarise the evidence in an 'Overview of reviews' table which we will populate with the summary risk estimate and 95% confidence interval, number of participants, and the quality of evidence for each outcome, grouped by intervention topic, timing of intervention (preconception, interconception and during pregnancy) and whether GDM was a primary or secondary outcome.
Quality of included studies within reviews
We will not reassess the quality of included studies within reviews, but instead will report study quality according to the review authors' assessment. In the case that individual studies are included in two or more Cochrane Reviews, we will report this, and any variation regarding review authors' assessments of study quality. We will collect this information during the data extraction process. We will resolve disagreements by discussion.
Data synthesis
We will undertake a narrative description of the included Cochrane systematic Reviews, and their summary statistics. We will not examine indirect comparisons and will not conduct network meta-analyses. We will summarise the main results of the included reviews by categorising their findings in the following framework, organised by timing of intervention (preconception, interconception and during pregnancy), and by intervention topic.
• Effective interventions: indicating that the review found high-quality evidence of effectiveness for an intervention.
• Possibly effective interventions (more evidence needed): indicating that the review found moderate-quality evidence of effectiveness for an intervention, but more evidence is needed.
• Ineffective interventions: indicating that the review found high-quality evidence of lack of effectiveness for an intervention.
• Probably ineffective interventions (more evidence needed): indicating that the review found moderate-quality evidence suggesting lack of effectiveness for an intervention, but more evidence is needed.
• No conclusions possible due to lack of evidence: indicating that the review found low-or very low-quality evidence, or insufficient evidence to comment on the effectiveness of an intervention.
The choice of category will reflect the information synthesised from the included reviews for the primary overview outcome (diagnosis of GDM). This approach to summarising the evidence is based on a Cochrane Overview of pain management in labour, which categorises interventions as "What works", "What may work", and "Insufficient evidence to make a judgement" (Jones 2012). 
A C K N O W L E D G E M E N T S
